# PITUITARY DISORDERS

HYPOPITUITARY SYNDROMES (_Lancet_ 2016;388:2403)

原因

• **Primary:** surgery, radiation (develops after avg 4–5 y), tumors (primary or metastatic), infection, infiltration (sarcoid, hemochromatosis), autoimmune, ischemia (including Sheehan’s syndrome caused by pituitary infarction intrapartum), carotid aneurysms, cavernous sinus thrombosis, trauma, medications (eg, ipilimumab), apoplexy

• **Secondary** (hypothalamic dysfunction or stalk interruption): tumors (including craniopharyngioma), infection, infiltration, radiation, surgery, trauma

臨床表現

• **Hormonal deficiencies:** ACTH, TSH, FSH and LH, GH, prolactin, and ADH

• **Panhypopituitarism:** deficiencies in multiple hormonal axes and including ADH

• **Mass effect:** headache, visual field Δs, cranial nerve palsies, galactorrhea

Central adrenal insufficiency: ↓ ACTH

• Sx similar to 1° adrenal insufficiency (see “Adrenal Disorders”) _except:_

no salt cravings or hyperkalemia (b/c aldo preserved)

no hyperpigmentation (b/c ACTH/MSH is not ↑)

Central hypothyroidism: ↓ TSH

• Sx of central hypothyroidism similar to 1° (see “Thyroid Disorders”) _except_ absence of goiter

• Dx with free T4 in addition to TSH, as TSH may be low or _inappropriately normal_

Hypoprolactinemia: ↓ prolactin

• Inability to lactate

Growth hormone deficiency: ↓ GH

• ↑ chronic risk for osteoporosis, fatigue, weight gain

• Dx with failure to ↑ GH with appropriate stimulus (eg, insulin tolerance test, glucagon stimulation, and macimorelin stimulation)

• GH replacement in adults controversial (_Annals_ 2003;35:419)

Central hypogonadism: ↓ FSH & LH

• 臨床表現: ↓ libido, impotence, oligomenorrhea or amenorrhea, infertility, ↓ muscle mass, osteoporosis

• Physical exam: ↓ testicular size; loss of axillary, pubic and body hair

• Dx with: ↓ a.m. testosterone or estradiol (also assess SHBG, esp. in obese) and ↓ or normal FSH/LH (all levels ↓ in acute illness, ∴ do not measure in hospitalized 病人)

• 治療: testosterone or estrogen replacement _vs._ correction of the underlying cause

Central diabetes insipidus: ↓ ADH

• Typically from mass lesion extrinsic to sella; pituitary tumor does not typically present with DI

• 臨床表現: _severe_ polyuria, _mild_ hypernatremia (_severe_ if ↓ access to H2O)

• Diagnostic studies: see “Sodium and Water Homeostasis”

### Pituitary apoplexy (_Endocr Rev_ 2015;36:622)

• Rapid expansion of pituitary tumor (typically adenoma) due to hemorrhage or infarction

• Sx include excruciating headache, diploplia, hypopituitarism

• Rx: immediate high-dose glucocorticoids; prompt surgical decompression if severe neurologic impairment or Δ MS; conservative management if mild

Diagnostic evaluation

• **Hormonal studies**

_Chronic:_ ↓ target gland hormone + ↓ or normal trophic pituitary hormone

_Acute:_ target gland hormonal studies may be _normal_

_Partial hypopituitarism is more common than panhypopituitarism_

• **Pituitary MRI:** pituitary protocol (contrast enhanced) recommended

治療

• **Replace deficient target gland hormones**

• Most important deficiencies to recognize and treat in inpatients are _adrenal insufficiency_ and _hypothyroidism;_ if both present, treat with glucocorticoids first, then replace thyroid hormone so as not to precipitate adrenal crisis

HYPERPITUITARY SYNDROMES

### Pituitary tumors (_JAMA_ 2017;317:516)

• 病生理: adenoma → excess of trophic hormone (if tumor fxnal, but 30–40% not) and potentially _deficiencies_ in other trophic hormones due to compression; cosecretion of PRL and growth hormone in 10% of prolactinomas

• 臨床表現: syndromes due to oversecretion of hormones (see below)

± mass effect: headache, visual Δs, diplopia, cranial neuropathies

• Workup: MRI brain pituitary protocol, hormone levels, ± visual field testing

if <10 mm, no mass effect, no hormonal effects, can f/up q3–6mo

Hyperprolactinemia (_NEJM_ 2010;362:1219; _JCEM_ 2011;96:273)

• Etiology

Prolactinoma (50% of pituitary adenomas)

Stalk compression due to nonprolactinoma → ↓ inhibitory dopamine → ↑ PRL (mild)

• Physiology: PRL induces lactation and inhibits GnRH → ↓ FSH & LH

• 臨床表現: **amenorrhea**, **galactorrhea**, **infertility**, ↓ libido, impotence

• Diagnostic studies

↑ **PRL** (✔ _fasting_ levels), but elevated in many situations, ∴ 排除 pregnancy or exogenous estrogens, hypothyroidism, dopamine agonists (eg, psych meds, antiemetics), renal failure (↓ clearance), cirrhosis, stress, ↑ carb diet. Watch for _hook effect:_ assay artifact yielding falsely low PRL if very high serum PRL levels; retest with sample dilution.

### MRI brain pituitary protocol

• 治療

If asx (no HA, galactorrhea, hypogonadal sx) & microadenoma (<**10 mm**), follow with MRI

If sx or macroadenoma (≥**10 mm**) options include:

_Medical_ with dopamine agonist such as cabergoline (70–100% success rate) or bromocriptine (not as well tol); side effects include N/V, orthostasis, nasal congestion

_Surgical:_ transsphenoidal surgery (main indications: failed or cannot tolerate medical Rx, GH cosecretion or neurologic sx not improving); 10–20% recurrence rate

_Radiation:_ if medical or surgical therapy have failed or are not tolerated

Acromegaly (↑ GH; 10% of adenomas; _NEJM_ 2006;355:2558; _JCEM_ 2014;99:3933)

• Physiology: stimulates secretion of insulin-like growth factor 1 (IGF-1)

• 臨床表現: ↑ soft tissue, arthralgias, jaw enlargement, headache, carpal tunnel

syndrome, macroglossia, hoarseness, sleep apnea, amenorrhea, impotence, diabetes

mellitus, acanthosis/skin tags, ↑ sweating, HTN/CMP, colonic polyps

• Diagnostic studies: _no utility in checking random GH levels because of pulsatile secretion_

↑ **IGF-1** (somatomedin C); ± ↑ PRL; OGTT → GH _not_ suppressed to <1 (<0.3 if newer assay) ng/mL; pituitary MRI to evaluate for tumor

• 治療: **surgery**, octreotide (long- and short-acting preparations), dopamine agonists (if PRL co-secretion), pegvisomant (GH receptor antagonist), radiation

• Prognosis: without Rx 2–3× ↑ mortality, risk of pituitary insufficiency, colon cancer

Cushing’s disease (↑ ACTH): 10–15% of adenomas; see “Adrenal Disorders”

Central hyperthyroidism (↑ TSH, ↑ α-subunit): extremely rare; see “Thyroid Disorders”

↑ FSH & LH: often non-fxn, may present as _hypopituitarism_ b/c compression effects

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Multiple Endocrine Neoplasia (MEN) Syndromes</b></p></td></tr><tr><td><p><b>Type</b></p></td><td><p><b>Main Features</b></p></td></tr><tr><td><p><b>1</b></p><p>(<i>MENIN</i> inactiv.)</p></td><td><p>Parathyroid hyperplasia/adenomas → hypercalcemia (~100% penetrance)</p><p>Pancreatic islet cell neoplasia (gastrin, VIP, insulin, glucagon)</p><p>Pituitary adenomas (fxn or non-fxn)</p></td></tr><tr><td><p><b>2A</b></p><p>(<i>RET</i> proto- oncogene)</p></td><td><p>Medullary thyroid carcinoma (MTC)</p><p>Pheochromocytoma (~50%)</p><p>Parathyroid hyperplasia → hypercalcemia (15–20%)</p></td></tr><tr><td><p><b>2B</b></p><p>(<i>RET</i> proto- oncogene)</p></td><td><p>Medullary thyroid carcinoma (MTC)</p><p>Pheochromocytoma (~50%)</p><p>Mucosal and gastrointestinal neuromas</p></td></tr></tbody></table>

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Autoimmune Polyglandular Syndromes (APS)</b> <span>(</span><span><i>NEJM</i></span> <span>20</span><span>1</span><span>8;378:</span><span>11</span><span>32)</span></p></td></tr><tr><td><p><b>Type</b></p></td><td><p><b>Features</b></p></td></tr><tr><td><p><b>I</b> (child onset)</p></td><td><p>Mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency</p></td></tr><tr><td><p><b>II</b> (adult onset)</p></td><td><p>Adrenal insufficiency, autoimmune thyroid disease, diabetes mellitus type 1</p></td></tr></tbody></table>
